Two Common Antiseizure Medications Do Not Harm Child Neurodevelopment
By Lori Solomon HealthDay Reporter
TUESDAY, Dec. 3, 2024 -- Fetal exposure to two common antiseizure medications (ASMs) does not seem to negatively impact children's neurological development at age 6 years, according to a study published online Nov. 25 in JAMA Neurology.
Kimford J. Meador, M.D., from the Stanford University School of Medicine in Palo Alto, California, and colleagues compared the outcomes of 6-year-old children of women with epilepsy (WWE) versus those of healthy women to assess the association of outcomes to third-trimester ASM exposures. The analysis included 298 children of WWE and 89 children of healthy women.
The researchers found that the two groups of children did not differ on the Verbal Index Score, but there was variance based on the amount of ASM exposure. Lamotrigine showed positive exposure-dependent associations, while levetiracetam showed negative exposure-dependent associations. Across ASMs, exposure-dependent outcomes differed. Three-quarters of WWE (78 percent) were taking lamotrigine or levetiracetam alone or in combination, so assessment of other ASMs was limited. There were positive associations for folate supplementation during the first 12 weeks of pregnancy with cognition and behavior, with no signal for risks at higher folate doses.
"Because all ASMs are potential teratogens, and teratogens act in an exposure-dependent manner, the clinical challenge is to provide a dose sufficiently high to protect the mother and fetus from seizures but at the lowest effective concentration to minimize fetal risks," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-12-04 06:00
Read more
- Expanding Access to Obesity Medications Could Avert 42,000 Deaths/Year
- FDA Proposes Ban on a 'Useless' Decongestant, Phenylephrine
- Program Tripled Number of Completed At-Home Colon Cancer Tests
- FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan (sac-TMT) for the Treatment of Certain Patients With Previously Treated Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer With EGFR Mutations
- Heat Waves Linked to Adverse Health Outcomes for Seniors
- Opioid Use Treatment at Intervention Clinics Continues to Rise for Third Year
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions